KALA BIO Reports First Quarter 2025 Financial Results and Provides Corporate Update
KALA BIO Reports First Quarter 2025 Financial Results and Provides Corporate Update GlobeNewswire May 14, 2025 — Ongoing patient enrollment in Phase 2b CHASE trial of KPI-012 in Persistent Corneal Epithelial Defect (PCED); topline data anticipated in 3Q 2025 — — Cash resources of $42.2 million as of March 31, 2025, expected to fund operations […]